Novel drugs to treat hemophilia.
BACKGROUND
Hemophilia management requires replacement of the deficient clotting factor. Inhibitor development complicates treatment, and the implementation of and adherence to prophylaxis, considered the standard of care for severe hemophilia, is hampered by the high cost and the need for frequent intravenous infusions. New, less expensive therapies are needed to reduce morbidities, enhance convenience and improve outcomes.


METHODS
We conducted a search of the Medline database from 1990 to 2010 for English language articles pertaining to hemophilia drug therapy. More than 4000 citations were obtained and examined for topic relevance. Additionally, proceedings from the American Society of Hematology, International Society on Thrombosis and Hemostasis, World Federation of Hemophilia, National Hemophilia Foundation and European Association for Haemophilia and Allied Disorders and the ClinicalTrials.gov website were reviewed for relevant publications and information.


RESULTS
This article summarizes current research efforts focused on developing less immunogenic and more potent and/or longer-acting clotting factor concentrates that uniquely promote hemostasis, are more affordable and do not require intravenous administration.


CONCLUSIONS
The availability of orally administered clotting factors will truly transform the lives of hemophilia patients and their families and caregivers.
Valentino
Leonard A
LA
Hemophilia and Thrombophilia Center, Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL 60612-3833, USA. lvalentino@rush.edu
Ismael
Yousef
Y
Grygotis
Michele
M
D000818:Animals; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D015195:Drug Design; D006467:Hemophilia A / Q000503:physiopathology / Q000628:therapy*; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D055118:Medication Adherence; D012720:Severity of Illness Index
D001779:Blood Coagulation Factors